Treatment with paliperidone in children with behavior disorders previously treated with risperidone: An open-label trial

Clinical Neuropharmacology

Volumn 35, Issue 5, 2012, Pages 227-230

  Fernández Mayoralas, Daniel Martín ^a   Fernández Jaén, Alberto ^a   Muñoz Jareño, Nuria ^b   Calleja Pérez, Beatriz ^a   Fernández Perrone, Ana Laura ^a   Arribas, Sonia López ^c  

^a Hospital Universitario Quiron Madrid   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c Centro CADE   (Spain)

Author keywords

Aggression; conduct disorder; disruptive behavior disorders; paliperidone; risperidone

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PALIPERIDONE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; AGGRESSION; AKATHISIA; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; HYPERPROLACTINEMIA; IRRITABILITY; LOW DRUG DOSE; MALE; MENTAL DEFICIENCY; MORNING DOSAGE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OVERT AGGRESSION SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALIVATION; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; DEVELOPMENTAL DISABILITIES; DRUG SUBSTITUTION; FEMALE; HUMANS; ISOXAZOLES; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIMIDINES; RISPERIDONE; TREATMENT OUTCOME;

EID: 84866564761     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31826818cd     Document Type: Article

References (25)

1. Pani L, Marchese G. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv 2009;6:319-331.
2. Boom S, Talluri K, Janssens L, et al. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009;49:1318-1330.
3. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 2008;69(Suppl 4):9-14.
4. Caldwell MF, Malterer M, Umstead D, et al. A retrospective evaluation of adjunctive risperidone treatment in severely behaviorally disordered boys receiving psychosocial treatment. J Child Adolesc Psychopharmacol 2008;18:34-43. (Pubitemid 351311240)
5. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. U.S. Department of Health, Education, andWelfare Publication (ADM). Rockville, MD: National Institute of Mental Health; 1976.
6. Hellings JA, Nickel EJ, Weckbaugh M, et al. The overt aggression scale for rating aggression in outpatient youth with autistic disorder: Preliminary findings. J Neuropsychiatry Clin Neurosci 2005;17:29-35. (Pubitemid 40283767)
7. Strous RD, Golubchik P, Maayan R, et al. Lowered DHEA-S plasma levels in adult individuals with autistic disorder. Eur Neuropsychopharmacol 2005;15:305-309. (Pubitemid 40487734)
8. Spivak B, Golubchik P, Mozes T, et al. Low platelet-poor plasma levels of serotonin in adult autistic patients. Neuropsychobiology 2004;50:157-160. (Pubitemid 39077836)
9. Canuso CM, Turkoz I, Sheehan JJ, et al. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. J Affect Disord 2010;120:193-199.
10. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-1892. (Pubitemid 44663390)
11. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-1370. (Pubitemid 350180724)
12. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res 2007;90:147-161. (Pubitemid 46178537)
13. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-130. (Pubitemid 46817944)
14. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia. A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27:6-14. (Pubitemid 46105757)
15. Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009;166:691-701.
16. Angelucci F, Ricci V, Martinotti G, et al. Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: A case report. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1277-1278.
17. Roser P, Haussleiter IS, Juckel G, et al. Paliperidone in an adult patient with Asperger syndrome: Case report. Pharmacopsychiatry 2009;42:78-79.
18. Schwartzer JJ, Morrison RL, Ricci LA, et al. Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression. Psychopharmacology (Berl) 2009;203:653-663.
19. Stigler KA, Erickson CA, Mullett JE, et al. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol 2010;20:75-78.
20. Kowalski JL, Wink LK, Blankenship K, et al. Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacol 2011;21:491-493.
21. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520.
22. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(Suppl 16):18-23. (Pubitemid 37523324)
23. Karlsson P, Dencker D, Nyberg S, et al. Pharmacokinetics and dopamine d2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 2005;15(Suppl 3):385.
24. Paesschena WV, Haumanb H, Lagaec L. The use of generic medication in epilepsy: A review of potential issues and challenges. Eur J Paediatr Neurol 2009;13:87-92.
25. Calarge CA, Miller DD. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol 2011;21:163-169.